PMID: 6989429Feb 16, 1980Paper

Prolongation of canine pancreas allograft survival with cyclosporin A: preliminary report

British Medical Journal
P McMasterD J Smith


Studies were conducted on dogs to test the efficacy of cyclosporin A (CyA) in prolonging normoglycaemia and graft survival after whole-organ pancreas allograft transplantation. Five dogs subjected to pancreatectomy alone served as controls. Withholding immunosuppression after transplantation (five animals) resulted in the same median duration of survival as occurred in the controls (13 days). Azathioprine and steroids (seven animals) produced median durations of normoglycaemia and survival of 9 and 23 days respectively. Animals given CyA 18 mg/kg/day (five) and 25 mg/kg/day (10), however, showed median durations of normoglycaemia of 18 and 55 days (p less than 0.05 and p less than 0.02) respectively and median survival times of 36 and 85 days (NS and p less than 0.02). If CyA proved effective in controlling rejection of pancreas allografts in man it would offer unstable diabetics in renal failure a more hopeful outlook than conventional immunosuppression.


Jul 1, 1976·Agents and Actions·J F BorelH Stähelin
Jan 1, 1979·Biographical Memoirs of Fellows of the Royal Society·H E Shortt, P C Garnham
Mar 1, 1965·American Journal of Public Health and the Nation's Health·H H MARKS


Apr 1, 1984·World Journal of Surgery·D W Gray, P J Morris
Apr 1, 1984·World Journal of Surgery·P McMasterT Vlassis
Mar 26, 2004·Transplantation Proceedings·W J Hogan, Rainer Storb
Mar 21, 1981·British Medical Journal·R Y CalneR Williams
Apr 1, 1984·World Journal of Surgery·D F Du ToitE A van der Merwe
Nov 1, 1980·The British Journal of Surgery·R Y Calne
Jun 1, 1988·Journal of Surgical Oncology·D F Du Toit, J J Heydenrych

Related Concepts

Blood Glucose
Canis familiaris
Graft Survival
Immunosuppressive Agents
Cyclic Peptides
Postoperative Period
Transplantation, Homologous
Pancreas Transplantation

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes
H BryngerG Claes
European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes
V Mirkovitch, M Campiche
© 2021 Meta ULC. All rights reserved